Forest Gains Takeover Option in Antibiotic Development Deal with Nabriva Therapeutics
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 6 (Table of Contents)
Published: 11 Jun-2012
DOI: 10.3833/pdr.v2012.i6.1752 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Forest Laboratories has agreed to pay US$25 M upfront to co-fund and co-develop Nabriva Therapeutics’ pleuromutilin antibiotic BC-3781 over the next 12 months...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS